|Articles|February 9, 2023

uMotif, ActiGraph Improve Patient's Wearable Experience

Alliance helps patients manage ePRO and wearables in one place.

eCOA/ePRO solutions provide uMotif has joined ActiGraph’s Accelerant™ Partner Program, to combine their solutions. ActiGraph, a provider of wearable remote monitoring technology, and the uMotif solution will allow sponsors and CROs to engage patients and provide a design-led approach to capture both subjective ePRO and objective device data through a single experience.

Read more about the joint eCOA/ePRO and wearable technology solution.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

uMotif, ActiGraph Improve Patient's Wearable Experience

Newsletter

Related Content

Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer

Adaptive Trial Design as a Pathway to Faster Development

After the Trial is too Late: The Case for More Active Use of Patient-Reported Outcomes in Oncology Studies

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

Trending on Applied Clinical Trials Online

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer

Applied Clinical Trials: October 2025 Interactive Digital Edition

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

In With the New